Monoclonal anticarcinoembryonic antigen (antiCEA), human milk factor globulin (HMFG2), and antikeratin antibodies were assessed for their value in the differential diagnosis of pleural mesothelioma (53 cases) and carcinoma of the lung (60 cases) in material from necropsies. In 40 of the cases pleural biopsies were also studied in the same manner. AntiCEA was found to be the best discriminating antibody for most types of mesothelioma; HMFG2 was slightly less valuable but a useful additional tool. Antikeratin was the least useful. For both antiCEA and HMFG2 antibodies, however, the proportion of carcinomas staining was smaller than in previous studies and this, combined with the positive staining of some mesotheliomas, reduces the value of the reactions in the individual case. Medical panels adjudicating compensation claims should not use these reactions as the sole criteria in deciding the origin of the tumours in these cases.
The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma V M Joglekar, D Oliver, M Harris Abstract Monoclonal anticarcinoembryonic antigen (antiCEA), human milk factor globulin (HMFG2), and antikeratin antibodies were assessed for their value in the differential diagnosis of pleural mesothelioma (53 cases) and carcinoma of the lung (60 cases) in material from necropsies. In 40 of the cases pleural biopsies were also studied in the same manner. AntiCEA was found to be the best discriminating antibody for most types of mesothelioma; HMFG2 was slightly less valuable but a useful additional tool. Antikeratin was the least useful. For both antiCEA and HMFG2 antibodies, however, the proportion of carcinomas staining was smaller than in previous studies and this, combined with the positive staining of some mesotheliomas, reduces the value of the reactions in the individual case. Medical panels adjudicating compensation claims should not use these reactions as the sole criteria in deciding the origin of the tumours in these cases. Paraffin sections (4 p) from the 60 pleural biopsies and 113 postmortem tumour blocks were routinely stained with haematoxylin and eosin. They were surveyed to ensure that tumour cells were present for staining. In the case of 12 pleural biopsies no malignant cells were seen and these were excluded from the study.
Further 4 ,u sections were cut for the alkaline phosphatase antialkaline phosphatase (APAAP) immunostaining technique. Eight pleural biopsy cases now had insufficient cells for immunostaining and these were excluded from the study leaving 40 pleural biopsies for analysis (13 carcinomas, 17 mesotheliomas). The sections were labelled numerically by one of us (DO), who was aware of the diagnosis. The sections were mounted with starch adhesive and allowed to dry for 30 minutes at 60°C. Sections were treated with trypsin for 20 minutes, stained by the APAAP immunoalkaline staining method as previously described,"3 and mounted with glycerine jelly.
The stained sections were then assessed independently and blindly by two ofus (VMJ, MH). Staining was considered positive when most cells showed the reddish reaction product or negative if no reaction was observed. The two assessments were then correlated with each other and with the pleural biopsy and postmortem diagnosis at the end of the study.
REAGENTS
The antibodies AE1/AE3 (low molecular weight antikeratin mouse monoclonal antibody), HFMG2 (supernatant), and antiCEA mouse monoclonal antibodies were supplied by Oxoid Ltd, Wade Road, Basingstoke, Hampshire RG24 OPW. The antiCEA antibody had not been absorbed with spleen powder to remove immunoreactive activity to non-specific reaction antigen.
Positive controls consisted of tumour from colon (antiCEA), skin (antikeratin), and breast (HMFG2). Negative controls were the same but with no antibody.
Results Tables 1 and 2 summarise the immunohistochemical results.
Discussion
In this study we attempted to assess the value of three commonly used antibodies in the differentiation of malignant pleural mesothelioma from carcinoma involving the pleura.
We investigated a series ofnecropsy cases comprising carcinomas ofvarious histological types, in which the diagnosis had been authenticated by the local pneumoconiosis panel and in which the carcinoma clinically and radiologically mimicked mesothelioma. In 40 of the 1 13 cases biopsy material was also studied. Postmortem confirmation of the original diagnosis, a useful end point, has not been a feature of some studies,"4 whereas other studies'9 have attempted to get postmortem confirmation of their diagnosis but did not succeed in all the cases.
No specific tumour markers have yet been recognised for mesothelioma. As this tumour features in any differential diagnosis of lung carcinoma, particularly involving pleura, various authors'9 have used panels of antibodies in an effort to achieve this differentiation. Early studies''3 used polyclonal antibodies but later, as monoclonal antibodies became available, these were used. The diagnosis ofpleural mesothelioma at necropsy examination is an important problem for the pathologist as the success or failure of individual compensation claims can hinge on that person's conclusions. In this study we have shown that in most cases immunohistochemistry on material from necropsy accurately reflects the results obtained in biopsies from the same patients, suggesting that it is a valid diagnostic procedure. Although our results confirm that antiCEA and HMFG2 are useful in distinguishing mesothelioma from carcinoma, we found a smaller proportion of carcinomas in general and adenocarcinomas in particular staining with the two antibodies than most other workers. This, taken together with our finding and those in other series that a number of mesotheliomas are positive for antiCEA and HMFG2 reduces the value of the staining reactions when applied to the individual case. They should not, therefore, be used as the sole criteria by medical panels in deciding the origin of a given tumour for mesothelioma compensation claims. 
